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Previewspreviously associated with shRNA-medi-
ated knockdown of Cbx7 (Gil et al.,
2004). Strikingly, when expressed in
ESCs, miR-125 and miR-181 downregu-
lated Cbx7 expression and promoted
differentiation, providing direct evidence
that miR regulation of PcG proteins is
a determining factor in maintenance of
self-renewal in pluripotent cells.
In their final experiment Morey et al.
demonstrate that ESCs depleted of
Cbx7, Cbx4, and Cbx2 can form tera-
tomas in vivo. This was not entirely unex-
pected considering previous work has
shown that teratomas can be formed
even in the absence of PRC1 (Leeb et al.,
2010). The authors assert that the tera-
toma formation is skewed toward the
ectodermal lineage for grafts depleted of
Cbx7 and the endodermal and meso-
dermal lineage for grafts depleted Cbx2
and Cbx4. Although this in vivo data is
somewhat qualitative, it is consistent with
expression data from Cbx7, Cbx2, and
Cbx4 knockdowns. The role of the Cbx/
PRC1 complex specificity as it relates to6 Cell Stem Cell 10, January 6, 2012 ª2012 Edifferentiation into the three germs layers
needs to be further explored both in vitro
and in vivo. Another interesting question
not addressed in either paper is how PcG
complexes are regulated when differenti-
ated cells are returned to a pluripotent
state using iPS technology. It would be
interesting and informative to see if
Cbx7/PRC1 complexes are reformed
with a return to pluripotency and if these
complexes function to transcriptionally
re-repress Cbx2, 4, and 8. Nonetheless,
these reports mark a significant step
toward understanding how PcG proteins
are regulated in ESCsand how this regula-
tion helps modulate the fine balance
between self-renewal and differentiation
in pluripotent cells.REFERENCES
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Mesenchymal stem cells (MSCs) are a promising source for bone regeneration. Recently, inNature Medicine,
Liu et al. (2011) reported that host lymphocytes secrete IFN-g and TNF-a to initiate apoptosis of transplanted
MSCs and that aspirin can alleviate these effects to improve bone repair.The skeletal system provides unique
niches for maintaining a permanent he-
matopoietic stem cell (HSC) pool, from
which all cells of the immune system
derive, and for the differentiation and
maturation of immune cells. Osteoblasts,
which are derived from mesenchymal
stem cells (MSCs), and cells of the
myeloid lineages provide key factors forthe HSC microenvironment during devel-
opment and adulthood (Askmyr et al.,
2009). Lymphocytes are known to contin-
uously migrate through the bone marrow
but the precise physiology of this cell
traffic is poorly understood. It is, however,
well established that certain lymphocyte
subsets such as long-lived memory T
and B cells reside in specialized nichesin the bone marrow (Tokoyoda et al.,
2009). Defining cellular interactions be-
tween immune cells and the bone tissue
in which they reside is an important goal
of the newly emerging osteoimmunology
field, and such insights may also be help-
ful for designing improved protocols
for MSC-mediated bone repair and/or
regeneration.
Figure 1. Proinflammatory T Cells Govern MSC-Based Bone Regeneration
MSC infusion promotes bone repair. This function is regulated by IFN-g and TNF-a produced by CD4+T
cells. IFN-g exerts its inhibition on osteogenetic differentiation of MSCs through Fas to downregulate
Runx2 expression and upregulate Smad6 expression. When both IFN-g and TNF-a are present, MSCs
undergo apoptosis.
Cell Stem Cell
PreviewsMSCs offer unprecedented opportuni-
ties for bone repair and bone engineering.
A large number of preclinical and clinical
studies have demonstrated that exoge-
nously added MSCs alone or in com-
bination with biomaterial scaffolds can
generate new bone and bone-associated
tissues to replace or restore the function
of traumatized or lost bone as a conse-
quence of aging or disease (Deschaseaux
et al., 2009). Sites of tissue damage are
always undergoing either chronic or acute
immune responses, and MSCs migrating
to these sites will therefore encounter
various immune cells in the local environ-
ment as they execute their repair function
(Shi et al., 2010). Immune cells are a rich
source of numerous cytokines that can
affect the fate of bone cells during bone
remodeling and disease. For example,
factors produced by lymphocytes and
other mononuclear cells can dramatically
influence bone turnover by altering the
delicate balance between bone formation
and bone resorption, processesmediated
by osteoblasts and osteoclasts, respec-
tively (Raggatt and Partridge, 2010).
Recently, the therapeutic effect of MSCs
in graft-versus-host disease in mice was
found to be critically dependent on
MSCs initiating cytokine and nitric oxide
(NO) signaling to block the activity of
migrating T cells (Ren et al., 2008). These
data show that complex crosstalk
between implanted MSCs and recipient
immune cells in a disease setting plays akey role in determining therapeutic out-
come. However, whether similar mecha-
nisms are at play during MSC-based
bone regeneration and whether specific
subsets of T cells present in bone may
play unique roles to affect therapeutic
efficacy remains unclear.
In a recent issue of Nature Medicine
(Liu et al., 2011), Dr. Songtao Shi’s group
presents findings that provide novel
insight into how the host immune systems
communicates with transplanted MSC
during bone formation and repair. In their
first sets of experiments, Liu et al. grafted
autologous bone-marrow-derived MSCs
(BMMSCs) together with carrier hydroxy-
apatite tricalcium phosphate (HA-TCP)
particles and assayed subcutaneous
bone formation. The authors found that
no bone formation occurred when
BMMSCs were implanted into immune
competent C57BL/6 mice but that im-
plants into immune incompetent ‘‘nude’’
mice showed significant bone growth. In
subsequent experiments, the authors
used the mouse BMMSC implant model
to dissect out components of the host
immune system responsible for the
effects observed on bone generation.
Pan T cells infused prior to BMMSC
implantation blocked bone formation in
nude mice, but Liu et al. found that this
effect was specifically mediated by
CD4+CD25 T cells. In contrast, regula-
tory CD4+CD25+ Treg cells did not block
bone generation in nude mice and wereCell Stem Celfound to rescue bone formation when
infused into C57BL/6 mice. The implant
data also revealed that IFN-g and TNF-a
produced by the distinct T cell subsets
appeared to play a critical role in deter-
mining the outcome for the implanted
BMMSCs.
The authors next set out to investigate
the cellular signaling pathways underpin-
ning these effects. Treatment of BMMSCs
in vitro with IFN-g alone blocked osteo-
genic differentiation and induced up-
regulation of Smad6, whereas IFN-g and
TNF-a in combination acted in synergy to
induce BMMSC apoptosis. IFN-g treat-
ment in itself induced Fas expression and
internalization in BMMSCs without acti-
vating caspase 3 and caspase 8, suggest-
ing that Fas signaling could play a role in
regulation of osteogenesis. Surprisingly,
when BMMSCs were treated with both
IFN-g and TNF-a, the nonapoptotic Fas
signaling pathway was converted to a
death pathway and triggered an apoptotic
cascade as a result of reduced levels of
anti-apoptotic factors NF-kB, XIAP, and
FLIP.Under theseconditions, Fas internal-
ization leads toactivationof caspase8and
caspase 3 to initiate apoptosis. Although
a combination of Fas loss-of-function
approaches provide compelling data that
Fas signaling is a critical mediator of this
form of apoptosis in BMMSCs, it is not
clear why these cells employ such a
unique mechanism to regulate apoptosis.
However, since both IFN-g and TNF-a
often coexist in vivo, it is likely that the
Fas-mediated death pathway dominates
in most inflammatory environments
(Figure 1). Indeed, the authors showed
that caspase blockade could effectively
promote bone formation, presumably by
enhancing the survival of BMMSCs.
Drawing from these observations,
Liu et al. next used a BMMSC-based
calvarial repair model to find conditions
that would improve the marginal repair
effects seen with BMMSCs and gelfoam
implants. Similarly to what they had
observedusing the implantbone formation
model, the authors found that systemic
infusion of Treg cells inhibited the produc-
tion of IFN-g and TNF-a and markedly
improved bone regeneration. Importantly,
Liu et al. also report that local administra-
tion of aspirin markedly improved bone
regeneration in the calvariar injury model.
In the nude mouse system, the authors
showed that infusion of CD4+CD25l 10, January 6, 2012 ª2012 Elsevier Inc. 7
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PreviewsT cells could inhibit bone formation by
boosting the production of IFN-g and
TNF-a. It is important to point out that
CD4+CD25 T cells are resting cells that
should produce little cytokine; however,
it is possible that these C57BL/6-derived
CD4+CD25 T cells may become acti-
vated due to the allogenicity of their
nude hosts. In their in vitro studies, the
authors demonstrated that FasL has no
role in the inflammatory cytokine-in-
duced apoptosis of BMMSCs. However,
whether FasL on T cells could contribute
to the demise of BMMSCs in this context
remains unknown. BMMSCs are known to
produce large amounts of chemokines
and nitric oxide (NO) in the presence
of inflammatory cytokines. Chemokines
then attract T cells into close proximity
with MSCs, where NO concentrations
are greatest (Ren et al., 2008). Since nitric
oxide is known to promote FasL-induced
apoptosis (Boyle et al., 2002), T cell-asso-8 Cell Stem Cell 10, January 6, 2012 ª2012 Eciated FasL may induce BMMSC
apoptosis in vivo.
Taken together, the findings of Liu
et al. provide insight into interactions
between the skeletal and immune system
in a graft/host environment and point to
strategies that may improve therapeutic
outcome for MSC-based tissue engi-
neering. The distinct roles T cell subsets
play inmediating communication between
immune cells and osteogenesis could also
be occurring during homeostatic bone
metabolism. A better understanding of
such mechanisms may help explain the
pathogenesis of some skeletal diseases
such as osteo-arthritic erosion and bone
loss during systemic lupus erythematosus.REFERENCES
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